Circumvent

Circumvent Pharmaceuticals, founded in 2017 and headquartered in the United States, is dedicated to addressing the unmet needs of neurodegenerative disease patients. The company focuses on heritable forms of neurodegeneration, aiming to facilitate drug discovery and development for both rare and common forms of neurodegenerative diseases. Notably, Circumvent has secured funding from prominent entities such as NIH/NINDS, YC Bio, Heritage Provider Network, and the Longevity Fund. The company's most recent investment, a $495.00K grant, was received on 01 November 2021. Positioned at the intersection of biotechnology, healthcare, and pharmaceutical industries, Circumvent Pharmaceuticals is making significant strides in combating neurodegenerative diseases, garnering support and resources from key players in the healthcare and investment sectors.